Lyell Immunopharma, Inc.

LYEL Nasdaq SEC CIK 1806952
Follow Lyell Immunopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $3K −80% vs same quarter last year
Net income −$45.5M −17.2% vs same quarter last year
EPS, diluted −$1.86 +12.7% vs same quarter last year
Operating cash flow −$34.6M −21% vs same quarter last year
Revenue by quarter
$11K
$7K
$8K
$15K
$6K
$2K
$4K
$3K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$36K−$274.4M
FY24$61K−$343M
FY23$130K−$234.6M
FY22$84.7M−$183.1M
FY21$10.7M−$250.2M
FY20$7.8M−$204.5M
FY19$657K−$129.4M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−800000%−600000%−400000%−200000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−748344.4%−762355.6%
FY24−588123%−562285.2%
FY23−190006.2%−180486.2%
FY22−220.9%−216.2%
FY21−2016.7%−2349.5%
FY20−2732.6%−2636.3%
FY19−15538.7%−19692.1%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$150.8M
FY24−$162.9M
FY23−$166.4M
FY22−$193.8M
FY21−$191.8M
FY20−$212.4M
FY19$23.4M
FY18-
Returned to shareholdersDividends paid and shares bought back
$0$5M$10M$15MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22$0
FY21$0
FY20$11.8M
FY19$185K
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Lyell Immunopharma
  • Healthcare median
−800000%−600000%−400000%−200000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearLyell ImmunopharmaHealthcare median
FY25−762355.6%−30.6%
FY24−562285.2%−47%
FY23−180486.2%−58%
FY22−216.2%−80.4%
FY21−2349.5%−71.8%
FY20−2636.3%−62.2%
FY19−19692.1%−46.2%
FY18-−49.6%